title: ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
authors.affiliation: Ege University Organ Transplantation and Research Center, Ege University Medical School, Bornova/Izmir, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Uslu
authors.forename: Y
authors.initials: Y
authors.lastname: Tokat
authors.forename: E
authors.initials: E
authors.lastname: Ok
authors.forename: A
authors.initials: A
authors.lastname: Unsal
authors.forename: O
authors.initials: O
authors.lastname: Ilkgul
authors.forename: H
authors.initials: H
authors.lastname: Kaplan
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005190:Family; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D019520:Living Donors; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine; D008775:Methylprednisolone